CDMO: EUROAPI Completes Acquisition of Biano 21st November 2023
EUROAPI announced the completion of the acquisition of BianoGMP, strengthening its CDMO expertise in the high-growth oligonucleotide market.
This acquisition further differentiates EUROAPI’s value proposition to support a broader client base across the whole oligonucleotide development continuum, from research to commercialization.
“We are delighted to welcome the talented people of Biano,” said Viviane Monges, EUROAPI’s Chief Executive Officer. “Biano has demonstrated a strong commitment to supporting clients with innovative oligonucleotide developments. I look forward to all that we will achieve together to sustainably meet clients’ and patients’ needs around the world through our complementarities.”
As planned, Biano will retain its corporate brand and become a EUROAPI company.